Aberrant METTL14 gene expression contributes to malignant transformation of benzene-exposed myeloid cells

Chao Wu1, Xin Yu1, Xiaoling Li2

  • 1Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

Insights

Benzene exposure increases N6-methyladenosine (m6A) RNA modification in bone marrow cells, driven by METTL14 overexpression. This promotes malignant proliferation, offering targets for leukemia prevention.

Area of Science:

  • Toxicology
  • Epigenetics
  • Hematology

Background:

  • Benzene causes leukemia via bone marrow toxicity, with epigenetics as a suspected mechanism.
  • The role of N6-methyladenosine (m6A) RNA modification in benzene-induced hematotoxicity is not well understood.

Purpose of the Study:

  • To investigate the role of m6A RNA modification in benzene-induced hematotoxicity.
  • To identify specific molecular targets for benzene-induced hematologic malignancies.

Main Methods:

  • In vivo bone marrow transplantation and competitive repopulation assays in benzene-exposed mice.
  • Whole transcriptome and RNA m6A methylation sequencing.
  • GEO database analysis, western blot, q-PCR, m6A RIP, and CLIP assays.

Main Results:

  • Benzene exposure upregulated RNA m6A modification levels and METTL14 expression in bone marrow LSK cells.
  • METTL14 expression positively correlated with benzene dose, and regulated mTOR and GFI1.
  • Upregulation of METTL14-mediated m6A modification activated mTOR-AKT signaling, causing malignant proliferation.

Conclusions:

  • METTL14-driven m6A modification is a key mechanism in benzene-induced hematotoxicity.
  • METTL14, mTOR, and GFI1 are potential early targets for preventing benzene-induced hematologic malignancies.